Periodontics · patient case question
Where does drug-influenced gingival enlargement characteristically BEGIN?
Patient case: Generalized gingival enlargement in a patient on multiple medications
Patient: Male, 45 years old
Chief Complaint: “My gums are growing over my teeth.”
Background: Epilepsy controlled on phenytoin for nine years. Hypertension on amlodipine. Renal transplant six years ago, on ciclosporin. Irregular brushing, no interdental cleaning.
Vital Signs: BP 136/86 mmHg · HR 76 bpm · T 98.2°F
Findings: Firm, pale, stippled gingival enlargement beginning at the interdental papillae and extending to cover up to a third of several clinical crowns, most marked anteriorly and on the labial surfaces. Heavy plaque and calculus. No ulceration, no fever, no lymphadenopathy.
Show answer and explanation
Correct answer: D. At the interdental papilla and free gingival margin
- A. The attached gingiva may become involved as the lesion enlarges, but it is not where the process starts, and involvement is secondary.
- B. The mucogingival junction is the boundary between keratinized attached gingiva and alveolar mucosa. Drug-influenced enlargement characteristically STOPS at this line rather than starting there — a useful diagnostic feature, since it distinguishes the condition from diffuse swellings that cross it.
- C. Alveolar mucosa is non-keratinized and lies beyond the mucogingival junction. Drug-influenced enlargement does not involve it.
- D. CORRECT. Enlargement begins as a painless beadlike swelling of the INTERDENTAL PAPILLA and the FREE (marginal) gingiva. The papillae enlarge first, then coalesce with the marginal tissue to produce a lobulated mass that can cover the crowns. The anterior labial gingiva is affected most, and the process does not extend beyond the mucogingival junction.
Note: All three drug classes are represented in this patient and they act on the same target: ANTICONVULSANTS (phenytoin, roughly 50% of users), CALCIUM CHANNEL BLOCKERS (nifedipine, amlodipine, around 10–20%) and IMMUNOSUPPRESSANTS (ciclosporin, about 25–30%; tacrolimus much less). Ciclosporin combined with a calcium channel blocker is the highest-risk combination of all — as here.